Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 3/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | ALDH5A1 | P51649 | 3/20 | 0.47 |
| ▸ | ABAT | P80404 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | P4HB | P07237 | 2/20 | 0.44 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29452390 | 1.00 | KDM4E (0.57) | KDM4EPTGS2RAB9AAPPKIF11 | |
| SCHEMBL24445838 | 0.84 | KDM4E (0.57) | KDM4EPTGS2RAB9AAPPKIF11 | |
| SCHEMBL13257342 | 0.83 | KDM4E (0.61) | KDM4EPTGS2RAB9AALDH5A1ABAT | |
| SCHEMBL16552545 | 0.81 | HSD17B1 (0.54) | KDM4EPTGS2RAB9AAPPKIF11 | |
| SCHEMBL472408 | 0.81 | KIF11 (0.56) | KDM4EPTGS2RAB9AAPPKIF11 | |
| SCHEMBL2632511 | 0.80 | PTGS2 (0.57) | KDM4EPTGS2RAB9AALDH5A1ABAT | |
| SCHEMBL7879191 | 0.80 | TRPA1 (0.47) | PTGS2APPALDH1A1P4HBNQO2 | |
| SCHEMBL30500661 | 0.80 | PTGS2 (0.57) | KDM4EPTGS2RAB9AALDH5A1ABAT | |
| SCHEMBL6855509 | 0.79 | KIF11 (0.50) | KDM4EPTGS2RAB9AAPPKIF11 | |
| SCHEMBL11971419 | 0.78 | APP (0.60) | KDM4EAPPALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118546363-A | Polyimide film and production process thereof | 江苏韵升绝缘科技有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-114634429-B | Photosensitive diamine monomer and preparation method thereof, resin containing photosensitive diamine monomer and photosensitive resin composition | 波米科技有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-114634429-A | Photosensitive diamine monomer, preparation method thereof, resin containing photosensitive diamine monomer and photosensitive resin composition | 波米科技有限公司 | 2022-06-17 | — | — | CN | claimed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12527774-B2 | Estrogen-related receptor alpha modulators | LEAD PHARMA HOLDING B.V. (NL) | 2026-01-20 | — | — | US | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250268872-A2 | ESTROGEN-RELATED RECEPTOR ALPHA MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2025-08-28 | — | — | US | disclosed |
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250188044-A1 | TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION | HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037283-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037279-A1 | 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | KDM4E 1671/4885PTGS2 722/4885RAB9A 3588/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | KDM4E 4577/4885PTGS2 4119/4885RAB9A 1488/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | KDM4E 1626/4885PTGS2 509/4885RAB9A 3827/4885 |
| US-20250188044-A1 | TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION | PPARD, PPARA, PPARG | KDM4E 4377/4885PTGS2 2140/4885RAB9A 3419/4885 |
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | KDM4E 3786/4885PTGS2 191/4885RAB9A 3849/4885 |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | KDM4E 1630/4885PTGS2 1295/4885RAB9A 3641/4885 |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | KDM4E 623/4885PTGS2 4415/4885RAB9A 2454/4885 |
| US-12527774-B2 | Estrogen-related receptor alpha modulators | ESR2, ESRRA, ESRRB | KDM4E 350/4885PTGS2 1812/4885RAB9A 2274/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | KDM4E 1290/4885PTGS2 574/4885RAB9A 2943/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | KDM4E 1970/4885PTGS2 4573/4885RAB9A 2152/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | KDM4E 4045/4885PTGS2 2554/4885RAB9A 826/4885 |
| US-20250268872-A2 | ESTROGEN-RELATED RECEPTOR ALPHA MODULATORS | ESRRA, ESRRB, ESR2 | KDM4E 2358/4885PTGS2 1472/4885RAB9A 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.